Kjetil Tasken
Universitetet i Oslo
H-index: 75
Europe-Norway
Top articles of Kjetil Tasken
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
T cells with increased responsiveness cause obesity in mice without diet intervention | Iscience | Ida Gregersen Xiang Y Kong Sander Kooijman Håvard Foyn Helene Grannes | 2024/4/19 |
Evolutionary mode and timing of dissemination of high-grade serous carcinomas | JCI insight | Anita Sveen Bjarne Johannessen Solveig MK Klokkerud Sigrid M Kraggerud Leonardo A Meza-Zepeda | 2024/2/8 |
Small molecule inhibitors targeting regulatory T cells for cancer treatment | Nuria García‐Díaz Qian Wei Kjetil Taskén | 2024/2 | |
Hever kvaliteten på behandling av kreft | Tidsskrift for Den norske legeforening | Åslaug Helland Eli Sihn Samdal Steinskog Egil Støre Blix Åsmund Flobak Sigmund Brabrand | 2024/1/18 |
Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data | Cell Reports Methods | Alvaro Köhn-Luque Even Moa Myklebust Dagim Shiferaw Tadele Mariaserena Giliberto Leonard Schmiester | 2023/3/27 |
Modified study designs to expand treatment options in personalised oncology: A multi-stakeholder view | Christophe Le Tourneau Fabrice André Åslaug Helland Linda Mileshkin Warnyta Minnaard | 2023/8/4 | |
Standardized assays to monitor drug sensitivity in hematologic cancers | Cell death discovery | Pilar Ayuda-Durán Johanne U Hermansen Mariaserena Giliberto Yanping Yin Robert Hanes | 2023/12/1 |
P613: ANALYSIS OF EX-VIVO RESPONSE TO SINGLE DRUGS AND DRUG COMBINATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT SAMPLES | HemaSphere | Leonardo Miranda Santana Deepak B Thimiri Govinda Raj Andrea Cremaschi Mariaserena Giliberto Alexandra Gade | 2023/8/1 |
New therapeutic strategy targeting regulation of the SERCA2 complex protects from myocardial ischemia-reperfusion injury | European Heart Journal | A Calejo E Ostensen M Aronsen B Lygren J Skogestad | 2023/11 |
IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway. | Aslaug Helland Sigbjørn Smeland Hege Russnes Sigmund Brabrand Katarina Puco | 2023/6/1 | |
706P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway-Safety analysis of the first 126 patients included in the trial | Annals of Oncology | K Puco ES Samdal Steinskog ES Blix S Brabrand M Colban | 2023/10/1 |
1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine | Annals of Oncology | H Gelderblom A Edsjö HEG Russnes UN Lassen A Helland | 2023/10/1 |
Disruption of phosphodiesterase 3A binding to SERCA2 increases SERCA2 activity and reduces mortality in mice with chronic heart failure | Circulation | Jonas Skogestad Ingrid Albert Karina Hougen Gustav B Lothe Marianne Lunde | 2023/4/18 |
A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine | Cell death discovery | Johanne U Hermansen Yanping Yin Aleksandra Urban Camilla V Myklebust Linda Karlsen | 2023/4/13 |
1235P Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway | Annals of Oncology | A Helland GO Hjortland L Fagereng L Bjorge B Gilje | 2023/10/1 |
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma | Blood Advances | Ivana Spasevska Ankush Sharma Chloé B Steen Sarah E Josefsson Yngvild N Blaker | 2023/12/12 |
act synergistically against multiple myeloma cells | Application of drug sensitivity screening in B-cell malignancies for informing precision medicine strategies | Mariaserena Giliberto Deepak B Thimiri Govinda Raj Andrea Cremaschi Sigrid S Skånland Alexandra Gade | 2022 |
Functional testing of PI3K inhibitors stratifies responders to idelalisib and identifies treatment vulnerabilities in idelalisib-refractory/intolerant chronic lymphocytic leukemia | BioRxiv | Yanping Yin Paschalis Athanasiadis Linda Karlsen Aleksandra Urban Ishwarya Murali | 2022/4/15 |
P626: FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL | HemaSphere | Sigrid Skånland Yin Yanping Paschalis Athanasiadis Linda Karlsen Aleksandra Urban | 2022/6/1 |
Immunoregulatory signal networks and tumor immune evasion mechanisms: Insights into therapeutic targets and agents in clinical development | Qian Wei Kjetil Taskén | 2022/10/28 |
Co-Authors
